Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dolutegravir + abacavir/lamivudine versus Atripla in treatment-naive adults with HIV-1
2010-020983-39Phase 3Completed
- Sponsor
- ViiV Healthcare
- Start
- Nov 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of dolutegravir, abacavir, lamivudine and tenofovir disoproxil fumarate in Human immunodeficiency virus infection type 1 (2 arms), sponsored by ViiV Healthcare. Primary endpoint: Proportion of subjects with plasma HIV-1 RNA <50 copies/mL through Week 48. Started Nov 2010; status: completed.
02
Drugs
dolutegravirabacavirlamivudinetenofovir disoproxil fumarate
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2010-020983-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020983-39.